A Phase 1 Dose-Escalation Study of AEB1102 (Co-ArgI-PEG) in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Refractory to Hypomethylating Agents

Trial Profile

A Phase 1 Dose-Escalation Study of AEB1102 (Co-ArgI-PEG) in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Refractory to Hypomethylating Agents

Recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Oct 2017

At a glance

  • Drugs Pegzilarginase (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Sponsors Aeglea Biotherapeutics
  • Most Recent Events

    • 15 Aug 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Dec 2017.
    • 23 Mar 2017 According to an Aeglea Biotherapeutics media release, this trial is enrolling patients in cohort 3.
    • 15 Sep 2016 According to an Aeglea Biotherapeutics media release, data from this study are expected in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top